je.st
news
Tag: pharm
Streamlinging Pharm Drug Development: Yes, It's Time.
2016-06-01 14:14:49| drugdiscoveryonline Downloads
“We’ve always known that working with multiple CMOs is inefficient — there are handoff issues and no incentive for vendors to work together to speed the process. An integrated CDMO could eliminate many steps and save time by parallel processing other steps. Reducing time to milestone is a top priority for us — this would be highly valuable.” — Small pharma CEO1 The path from molecule to market isn’t getting any easier. The costs of drug development continue to rise. Dramatically. According to a 2015 report by Deloitte, costs have increased by a third in just the last five years2. If that weren’t trouble enough, sales during the same time frame have tumbled 50%3. Increased expenditure and decreased income are a bad combination — especially in an industry where the average cost to bring a new product to market approaches $2.6 billion4. It also helps explain why the ROI on R&D is also down 50%5. Obviously, these numbers are not sustainable in the long run. A fundamental change needs to be made, and soon. But this isn’t news. Nobody in the pharmaceutical industry is unaware of these trends — or their underlying meaning. So what’s the solution?
Tags: time
development
drug
pharm
Streamlining Pharm Drug Development: Yes, It's Time.
2016-06-01 14:14:49| drugdiscoveryonline Downloads
“We’ve always known that working with multiple CMOs is inefficient — there are handoff issues and no incentive for vendors to work together to speed the process. An integrated CDMO could eliminate many steps and save time by parallel processing other steps. Reducing time to milestone is a top priority for us — this would be highly valuable.” — Small pharma CEO1 The path from molecule to market isn’t getting any easier. The costs of drug development continue to rise. Dramatically. According to a 2015 report by Deloitte, costs have increased by a third in just the last five years2. If that weren’t trouble enough, sales during the same time frame have tumbled 50%3. Increased expenditure and decreased income are a bad combination — especially in an industry where the average cost to bring a new product to market approaches $2.6 billion4. It also helps explain why the ROI on R&D is also down 50%5. Obviously, these numbers are not sustainable in the long run. A fundamental change needs to be made, and soon. But this isn’t news. Nobody in the pharmaceutical industry is unaware of these trends — or their underlying meaning. So what’s the solution?
Tags: time
development
drug
pharm
Korea Pharm: Multisorb Introduces Sorbent Technology and Services for Pharmaceutical Companies
2016-03-16 11:31:10| Industrial Newsroom - All News for Today
Buffalo, New York - Multisorb Technologies will exhibit at Korea Pharm in Goyang, South Korea, April 26-29, 2016, and introduce how it can help companies stabilize their pharmaceutical or medical device packaging presentations with sorbent technology (desiccants and oxygen absorbers). For over 50 years, Multisorb...
Tags: services
technology
companies
korea
Underwriters buy additional $658 mln in Teva Pharm shares
2016-01-03 12:51:22| Biotech - Topix.net
Jan 3 The underwriters for Teva Pharmaceutical Industries' share offering last month have exercised their over-allotment option to purchase additional shares worth $658 million. Teva, the world's biggest generic drugmaker, will use the funds to finance the cash portion of its planned $40.5 billion purchase of Allergan PLC's Actavis generics business.
Tags: buy
additional
shares
additional buy
Teva Pharm to buy Mexican drugmaker Rimsa for $2.3 bln
2015-10-02 04:40:14| Biotech - Topix.net
Teva Pharmaceutical Industries has struck a deal to buy Mexican drugmaker Representaciones e Investigaciones Medicas SA for $2.3 billion to strengthen its presence in Latin America. It is Teva's second major acquisition in recent months.